卡培他滨联合多西他赛新辅助化疗治疗局部晚期乳腺癌疗效及安全性分析

目的 探讨卡培他滨与多西他赛的新辅助化疗方案对局部晚期乳腺癌的疗效及安全性。方法 对本院收治的46例局部晚期乳腺癌患者,在常规治疗的基础上,每个疗程的d1静脉点滴多西他赛（75 mg／m^2）,随后2周每天口服卡培他滨2次（1000 mg／m^2）,3周为一个疗程。如此持续3～4个疗程。分析其疗效及安全性。结果 临床疗效总有效率为84．8％（39／46）,其中5例（10．9％）为病理完全缓解。不良反应有粒细胞减少、脱发、手足综合征及腹泻等。结论 卡培他滨与多西他赛联合使用的化疗方案对局部晚期乳腺癌效果较好,依从性高,可供临床借鉴。

Analysis on the Efficacy and Safety of Capecitabine Combined with Docetaxel for Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer

Objective]To explore the efficacy and safety of capecitabine combined with docetaxel in neoadju‐vant chemotherapy of locally advanced breast cancer .[Methods]On the basis of conventional therapy ,46 patients with locally advanced breast cancer in our hospital were given intravenous instillation with docetaxel 75mg/m2 on the first day ,and then oral capecitabine 1000mg/m2 twice daily in the next 2 weeks .The duration was 3~4 cycles with 3 weeks a cycle .The efficacy and safety were analyzed .[Results] The total effective rate of clinical efficacy was 84 .8% （39/46） .Among them ,5 patients（10 .9% ） were pathologic complete remission .Adverse reactions were neutropenia ,alopecia ,hand‐foot syndrome ,diarrhea and so on .[Conclusion] Capecitabine combined with docetaxel in neoadjuvant chemotherapy for breast cancer has good efficacy and high compliance ,so it is well ad‐vised for clinical reference .